Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Common-Size Income Statement

Paying user area

Try for free

Bristol-Myers Squibb Co. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Bristol-Myers Squibb Co., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net product sales
Alliance and other revenues
Revenues
Cost of products sold, excludes amortization of acquired intangible assets
Gross margin
Marketing, selling and administrative
Research and development
Acquired IPRD
Amortization of acquired intangible assets
Operating income (loss)
Interest expense
Royalty income, divestitures
Royalty and licensing income
Provision for restructuring
Investment income
Integration expenses
Litigation and other settlements
Acquisition expense
Intangible asset impairment
Equity investment gains (losses), net
Loss on debt redemption
Divestiture gains (losses)
Other
Other income (expense), net
Earnings (loss) before income taxes
Income tax provision
Net earnings (loss)
Noncontrolling interest
Net earnings (loss) attributable to BMS

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Bristol-Myers Squibb Co. operating income (loss) as a percentage of revenues decreased from 2022 to 2023 and from 2023 to 2024.
Earnings (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Bristol-Myers Squibb Co. earnings (loss) before income taxes as a percentage of revenues increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS as a percentage of revenues increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.